Patent application number | Description | Published |
20090005862 | Stent and Method For Fabricating the Same - A stent includes a tubular stent body | 01-01-2009 |
20090131271 | METHOD FOR DELIVERING NUCLEIC ACID AND DEVICE FOR DELIVERING NUCLEIC ACID - In a method for delivering a nucleic acid of the invention, a nucleic acid is introduced into a cell by pressing the nucleic acid supported on a surface of a solid substrate against the cell. According to the method, the nucleic acid can be delivered into the cell simply at a low cost without placing a heavy burden on the cell at a high nucleic acid delivery efficiency. By allowing the surface of the solid substrate to support the nucleic acid in the form of a complex with a polyamine or a cationic lipid and pressing it against the cell, the introduction efficiency into the cell can be further improved. In the invention, by using a nucleic acid useful for gene therapy as the nucleic acid, a high-efficiency device for gene therapy can be obtained. | 05-21-2009 |
20090209942 | MEDICAL DEVICE HAVING DIAMOND-LIKE THIN FILM AND METHOD FOR MANUFACTURING THEREOF - A medical device includes a medial device body, and a diamond-like thin film covering the medical device body and containing silicon. The diamond-like thin film has a concentration of silicon which is lower in a surface thereof than in an interface thereof with the medical device body mentioned above, and continuously varies. | 08-20-2009 |
20100198344 | SUSTAINED DRUG-RELEASING STENT - A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight. | 08-05-2010 |
20110060403 | Stent and Method For Fabricating the Same - A stent includes a tubular stent body | 03-10-2011 |
20130115363 | METHOD OF MAKING A STENT - A method of making a stent, including preparing a solution containing a composition, the composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, including argatroban, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 3:7, the composition dissolved in a solvent selected from the group consisting of a mixture of a lower alkyl ketone and methanol, a mixture of a lower alkyl ester and methanol or a mixture of a lower halogenated hydrocarbon and methanol; coating at least an outer surface of a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces; and after the coating, removing the solvent to complete a first coated layer. | 05-09-2013 |
Patent application number | Description | Published |
20090048667 | Controlled Drug-Release Composition and Drug-Releasable Medical Device - A drug-releasable medical device contains a controlled drug-release composition comprising 100 parts by weight of an organic polymeric material which is soluble in an organic solvent and insoluble in water, 5 to 60 parts by weight of a lipid-soluble, low molecular weight release auxiliary agent and 1 to 70 parts by weight of a drug. When the composition is applied on a stent, a catheter, an organ replacement medical device, an artificial organ or the like in the form of coating or the like, the medical device is provided with a drug release function. Argatroban or sarpogrelate hydrochloride or both of them are gradually released from the surface of a stent for treating coronary artery stenosis, for example. In order to exhibit a sustained-release function for a desired period of time, the drug to be gradually released is carried in a polymeric material coated on a surface of a metal forming the stent or in a porous stent substrate. | 02-19-2009 |
20090062906 | Stent with autonomic function - To provide a stent which holds various performances such as deliverability, prevention of restenosis, flexible shape conformability, and so on and is therefore adaptable not only to a bile duct but also to a blood vessel system such as a tortuous coronary artery substantially without causing restenosis. | 03-05-2009 |
20090068054 | Ti-Ni-Nb alloy device - To provide a Ti—Ni—Nb alloy device which is a shape memory device excellent in response characteristics. | 03-12-2009 |
20090082848 | STENT - A stent includes a plurality of first portions arranged in a longitudinal direction, and second portions each disposed between the adjacent first portions. Each of the first portions is expandable and contractible in a radial direction, and each of the second portions allows a whole of the stent to curve in the longitudinal direction. When the first portion is expanded in the radial direction, the longitudinal length of the first portion is decreased, but spacing between the adjacent first portions is increased. | 03-26-2009 |